Top 17 AdvancesCombination Chemotherapy Extends Survival in Certain Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)
{"Image DocumentName": "Top 17 AdvancesCombination Chemotherapy Extends Survival in Certain Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)", "Image ImageDescription": "Phase III trial showed that combination of pemetrexed (ALIMTA\u00ae) and carboplatin (Paraplatin) therapy may extend survival for patients with NSCLC who have performance score of 2. The median overall survival was 5.1 months for patients treated with pemetrexed and 9.6 months for those treated with combination therapy.", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}